Leads Biolabs receives US FDA orphan drug designation for anti-PD-L1/4-1BB bispecific antibody, LBL-024 for treatment of neuroendocrine cancer: Nanjing, China Saturday, November 2 ...

Panelist discusses how the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer is evolving to address current unmet needs and offers clinical pearls to community oncologists ...

SINTEF has also signed a licence agreement with a pharmaceutical company. We're very confident that this approach may offer us a new cure for lung cancer." It was in many ways something of a ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study. The results could potentially lead to new therapies ...

Colorectal cancer is now the leading killer for those under 50. Two individuals have shared their experiences with Newsweek.

Discover how COVID-19 triggers the development of unique immune cells with anti-cancer properties, offering hope for new cancer treatment options.

The global neuroendocrine carcinoma treatment market is poised for substantial growth, with revenue expected to reach USD ...

Lung cancer is diagnosed by taking a biopsy from the suspicious area of the lung, which can be done with both bronchoscopy ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...